Distorted Earnings Due to $1.3 Billion Impairment Loss: Consumer Health Company Revises Adjusted Earnings

Perrigo Company plc (PRGO) submitted revised segment revenues and adjusted operating income for 2024–2025 and provided a detailed reconciliation of operating income from continuing operations to adjusted operating income by adjustment category.

The update reflects results for the Self-Care, Specialty Care and Infant Formula segments, as well as key pre-tax adjustments including intangible asset amortization, one-off litigation and restructuring costs, infant formula–related expenses, and asset impairments.

In 2025, Perrigo recognized $1.3 billion (about KRW 1.7 trillion) of goodwill impairment charges, in addition to impairments related to assets held for sale under the planned Richard Bitner business divestiture, the Prebaxid brand and its equity-method investment in Kazimira LLC. As a result, reported operating income was significantly lower than adjusted operating income.

In its February 26 announcement of full-year 2025 results, the company reported approximately $4.25 billion in revenue and a net loss of $1.43 billion (around KRW 2 trillion), and projected that full-year 2026 revenue could decline 1.5% to 5.5% year-over-year.

At the same time, Perrigo realigned its organization into four segments—Self-Care, Specialty Care, Infant Formula and Other—and updated its segment reporting to match the new structure.

Headquartered in Ireland, Perrigo operates a consumer health business in North America and Europe focused on over-the-counter pharmaceuticals and healthcare products, with strengths in retailer-branded generics and branded generics.

In the consumer health industry, demand is relatively stable given its essential nature, but profitability depends heavily on input costs, regulatory requirements and pricing negotiations with major retailers. As a result, companies continue to enhance their business profiles through product portfolio restructuring and cost-efficiency measures.